Business Context and Reporting Period
This Form 8-K filing by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) reports on the 2018 Annual Meeting of Shareholders held on December 21, 2018. The registrant is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The following matters were submitted to a vote and approved by shareholders:
- Quorum: 6,777,334 shares were present or represented by proxy out of 11,717,307 shares entitled to vote.
- Proposal 1 (Director Election): Dr. Francis Duhay and Dr. Sanjay Shrivastava were elected as Class I directors for a three-year term expiring in 2021. Both received 6,746,713 votes "For" and 6,017 votes "Withheld".
- Proposal 2 (Auditor Ratification): The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified. The vote was 6,771,317 "For", 5,654 "Against", and 363 "Abstaining".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the correct registrant name is Hancock Jaffe Laboratories, Inc., as the input metadata referenced "Envveno Medical Corp" which does not match the filing.
- Confirm the tenure of the newly elected Class I directors (Dr. Duhay and Dr. Shrivastava) through the 2021 Annual Meeting.
- Review the full 2018 Annual Report (Form 10-K) for the financial metrics absent from this 8-K filing.
- Check for any subsequent filings regarding the resignation or removal of the elected directors.